The Novo Nordisk Haemophilia Foundation (NNHF) was set up in 2005
with the vision that all people with haemophilia or allied bleeding
disorders receive care and treatment wherever they live.
One planet, different worlds
With proper diagnosis and care haemophilia and allied bleeding disorders are treatable. People can lead normal lives and have a near-normal life expectancy. This is not the situation everywhere. Particularly in the developing countries, where 80% of the global patient population lives1, still many patients go undiagnosed or are inadequately treated.
Committed to bridging the gap
Realising this situation and aiming to further bridging the existing gap, Novo Nordisk, a global Danish pharmaceutical company, established the NNHF. Its formation as a grant-making-non-profit organisation expresses Novo Nordisk's commitment to corporate social responsibility. Improving access to care on a global level is a key element of this approach to impacting change.
A vision comint to life
We firmly believe that our vision can only be achieved through a partnership approach, which is twinned with focused on the ground activities.
_________________________
1Source: https://unctad.org/en/PublicationChapters/tdstat42_FS11_en.PDF
